Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What LALPATHLAB guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 10 Nov 2026 | Dr. Lal PathLabs filed the transcript of its Q2 & H1 FY27 earnings conference call held on November 04, 2026. Management reported Q2 FY27 revenue of Rs. 874 crore, up 19.6%, and EBITDA of Rs. 280 crore (margin 32.1%); H1 FY27 revenue was Rs. 1,672 crore, up 19.4%. Management said Q2 PAT was Rs. 194 crore, up 27.5%,... NSE copy | No results filed since | ||
| 30 Jul 2026 | Dr. Lal PathLabs filed the transcript of its Q1 FY27 earnings conference call held on July 24, 2026. Management reported Q1 FY27 revenue of Rs. 798 crore, up 19.1% year-on-year, with EBITDA of Rs. 247 crore (31.0% margin) and PAT of Rs. 170 crore (21.4% margin). The board declared an interim dividend of 50% (Rs 5... NSE copy | +27.6 % | +19.6 % | -3.1 % |
| 06 May 2026 | Dr. Lal PathLabs filed the transcript of its Q4 & FY26 earnings conference call held April 30, 2026. Q4 FY26 revenue was Rs. 703 crore (up 16.6%); FY26 revenue was Rs. 2,763 crore (up 12.2%). Q4 FY26 EBITDA was Rs. 187 crore (26.6% margin); FY26 PAT was Rs. 510 crore. The Board approved a final dividend of Rs. 4... NSE copy | +28.0 % | +19.1 % | +3.9 % |
| 03 Feb 2026 | Dr. Lal PathLabs filed the transcript of its Q3 & 9M FY26 earnings conference call held on January 30, 2026. Q3 FY26 revenue was Rs. 660 crore, up 10.6% YoY from Rs. 597 crore; 9M FY26 revenue was Rs. 2,060 crore, up 10.8%. Q3 FY26 EBITDA before exceptional item was Rs. 179 crore (27.2% margin) after a one-time Rs.... NSE copy | - | - | +15.1 % |
| 06 Nov 2025 | Dr. Lal PathLabs filed the transcript of its Q2 and H1 FY26 earnings conference call held on October 31, 2025. Management said Q2 FY26 revenue was Rs. 731 crore (up 10.7% YoY) and H1 FY26 revenue was Rs. 1,400 crore (up 11%); Q2 PAT was Rs. 152 crore (up 16.4%) and H1 PAT was Rs. 286 crore (up 20%). Management said... NSE copy | -6.4 % | +10.6 % | +1.4 % |
| 05 Aug 2025 | Dr. Lal PathLabs filed the transcript of its Q1 FY26 and FY26 earnings conference call held on July 31, 2025. Management reported Q1 FY26 revenue of Rs. 670 crore, up 11.3% from Rs. 602 crore, and PAT of Rs. 134 crore, up 24.3%, with EBITDA margin of 28.7%. Management said the Board approved an interim dividend of... NSE copy | +16.6 % | +10.7 % | +3.8 % |
| 01 May 2025 | Dr. Lal PathLabs filed the transcript of its Q4 & FY25 earnings conference call held on April 25, 2025. Ved Prakash Goel (Group CFO) said Q4 FY25 revenue was Rs. 603 crore (up 10.5% from Rs. 545 crore) and FY25 revenue was Rs. 2,461 crore (up 10.5% from Rs. 2,227 crore). Q4 FY25 PAT was Rs. 156 crore (up 81.4%),... NSE copy | +24.4 % | +11.3 % | +0.8 % |
| 03 Feb 2025 | Dr. Lal PathLabs filed the transcript of its Q3 FY25 earnings conference call held January 30, 2025. Ved Goel (Group CFO) said Q3 FY25 revenue was Rs.597 crore, up 10.7% from Rs.539 crore, with EBITDA of Rs.154 crore (25.8% margin) and PAT of Rs.98 crore (up 19.3%). For nine months FY25, revenue was Rs.1,859 crore... NSE copy | +65.8 % | +20.5 % | -3.4 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 04 Nov 2026 | Management change | Dr. Lal PathLabs Limited filed the outcome of its board meeting held on November 04, 2026, approving unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The board declared a 2nd interim dividend of INR 5 per equity share (50% on face value of INR 10), with record... NSE copy |
| 04 Nov 2026 | Management change | Board of Dr. Lal PathLabs Limited, meeting held November 04, 2026, approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP. Declared 2nd interim dividend of INR 5 per equity share (50% on... NSE copy |
| 04 Nov 2026 | Management change | Board of Dr. Lal PathLabs Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP. Board declared a 2nd interim dividend of INR 5 per equity share (50% on face value of INR 10),... NSE copy |
| 30 Apr 2026 | Legal or regulatory, Management change | Board of Dr. Lal PathLabs approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended a final dividend of INR 4 per equity share (40% on face value of INR 10), subject to AGM approval, with record date June 26, 2026. Board approved acquisition of... NSE copy |
| 30 Apr 2026 | Legal or regulatory, Management change | Board of Dr. Lal PathLabs approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, and recommended a final dividend of INR 4 per equity share (40% on face value of INR 10), with record date June 26, 2026, subject to AGM approval. The Board approved acquisition of 100%... NSE copy |
| 30 Apr 2026 | Management change | Board meeting held April 30, 2026 approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditors' reports attached. Board recommended final dividend of INR 4 per equity share (40% on face value of INR 10) for FY2025-26, subject to AGM approval; record... NSE copy |
| 25 Mar 2026 | Credit rating | Dr. Lal PathLabs Limited intimated under Regulation 30 that CARE Ratings Limited, by letter dated March 25, 2026, upgraded the company's issuer rating. The issuer rating was upgraded to CARE AA+; Stable from CARE AA; Stable. The rating committee reviewed operational and financial performance for FY25 (audited) and... NSE copy |
| 31 Oct 2025 | Legal or regulatory | Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP. Board declared a 2nd interim dividend of INR 7 per equity share (70% of face value of INR 10) for FY... NSE copy |
| 31 Jul 2025 | Legal or regulatory | Board of Dr. Lal PathLabs Limited, meeting held on July 31, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP attached. The Board declared an interim dividend of INR 6 per equity share (60%... NSE copy |
| 31 Jul 2025 | Legal or regulatory | Board of Dr. Lal PathLabs Limited met on July 31, 2025 and approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP. The Board declared an interim dividend of INR 6 per equity share (60% on face value of INR... NSE copy |
| 31 Jul 2025 | Legal or regulatory | Board meeting held on July 31, 2025 approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP. The Board declared an interim dividend of INR 6 per equity share (60% on face value of INR 10) for FY 2025-26,... NSE copy |
| 25 Apr 2025 | Legal or regulatory, Management change | Dr. Lal PathLabs Limited filed the outcome of its board meeting held on April 25, 2025, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The board recommended a final dividend of INR 6 per equity share (60% on face value of INR 10), subject to member... NSE copy |
| 25 Apr 2025 | Legal or regulatory, Management change | Dr. Lal PathLabs' board, meeting held April 25, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with auditor reports attached. Board recommended a final dividend of INR 6 per equity share (60% on face value of INR 10) for FY2024-25, subject to... NSE copy |
| 25 Apr 2025 | Management change | Board of Dr. Lal PathLabs Limited, meeting held April 25, 2025, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with auditor reports attached (Deloitte Haskins & Sells LLP, consolidated audit report). Recommended final dividend of INR 6 per equity share... NSE copy |
| 22 Apr 2025 | Credit rating | Dr. Lal PathLabs Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated April 22, 2025. CARE Ratings Limited assigned an Issuer Rating of "CARE AA; Stable" to the company, with the rating action shown as "Assigned". The rating was assigned by CARE's Rating Committee and is... NSE copy |
| 14 Mar 2025 | Credit rating | Dr. Lal PathLabs Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated March 14, 2025. CARE Ratings Limited, by letter dated March 13, 2025, withdrew the credit rating on the Company's long term bank facilities of INR 104.17 crore, with immediate effect. The Company requested the... NSE copy |
| 30 Jan 2025 | Legal or regulatory | Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a limited review report from Deloitte Haskins & Sells LLP. Board declared a 3rd interim dividend of INR 6 per equity share (60% on face value of INR 10) for FY... NSE copy |
| 30 Jan 2025 | Legal or regulatory | Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a limited review report from Deloitte Haskins & Sells LLP. Board declared a 3rd interim dividend of INR 6 per equity share (60% on face value of INR 10) for FY... NSE copy |
| 30 Jan 2025 | Legal or regulatory | Board of Dr. Lal PathLabs approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with auditor's limited review report attached (Deloitte Haskins & Sells LLP, no modification noted). Board declared 3rd interim dividend of INR 6 per equity share (60%... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (19 in all). A list of what was filed, not a judgement of the company.